Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Testosterone Cypionate

FDA-approved product (injectable, injection), marketed as Azmiro, Depo-Testosterone, Testosterone Cypionate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Testosterone Cypionate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Hypogonadism
  • Hypogonadotropic hypogonadism
  • Klinefelter's syndrome
  • Neoplasm
  • Orchitis
  • Physiological sexual disorder
  • Sexual dysfunction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
3-oxoandrosten (4) derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis24.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Testosterone Cypionate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-10.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Testosterone Cypionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy

    NCT01378299 · start 2011-10-01

    Registered record
    Registry ID
    NCT01378299
    Conditions
    Hypogonadism
    Interventions
    Testosterone Cypionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-10-01
    Completion
    2017-11-07
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism
    InterventionTestosterone Cypionate
    PhasePhase 1
    Registry statusCompleted

  • A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer

    NCT01084759 · start 2010-03

    Registered record
    Registry ID
    NCT01084759
    Conditions
    Prostate Cancer
    Interventions
    Testosterone injection; Etoposide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-03
    Completion
    2014-10
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionTestosterone injection; Etoposide
    PhaseNot applicable
    Registry statusCompleted

  • Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients

    NCT00965341 · start 2009-09

    Registered record
    Registry ID
    NCT00965341
    Conditions
    Advanced Cancer
    Interventions
    Testosterone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-09
    Completion
    2012-09
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer
    InterventionTestosterone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa

    NCT00853502 · start 2008-12

    Registered record
    Registry ID
    NCT00853502
    Conditions
    Bone Metabolism
    Interventions
    testosterone cypionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2008-12
    Completion
    2016-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone Metabolism
    Interventiontestosterone cypionate
    PhasePhase 2
    Registry statusWithdrawn

  • Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo

    NCT00179517 · start 2001-06

    Registered record
    Registry ID
    NCT00179517
    Conditions
    Seizure Disorder; Hypogonadism; Erectile Dysfunction
    Interventions
    Anastrozole 1mg; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-06
    Completion
    2008-04
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeizure Disorder; Hypogonadism; Erectile Dysfunction
    InterventionAnastrozole 1mg; Placebo Oral Tablet
    PhasePhase 2
    Registry statusCompleted